91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Dr Ute Berger, President, Development & Commercialisation Solutions outlines how in the Executive Interview in Drug Development & Delivery.
Copyright Drug Development & Delivery.
-
As DCT adoption increases, Harpreet Gill, Head of Decentralised Clinical Trial Solutions at 91黑料 contributes to this piece in Clinical Trials Arena which looks at how sponsors and CROs must mind .
Verdict Media Limited 2022
-
If the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at 91黑料, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.
In this Jeff James, EVP Alliance Management, offers his perspective on what it takes to be a trusted partner to sponsors in the clinical development industry. -
.jpg?w=545&itok=7luDTQY4 "IPT discussed in technical publications.")
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines
This article is taken fromInnovations in Pharmaceutical Technology, October 2022, pages 34-36 . Samedan Ltd
-
Matt Harrington, VP of Connected Health Technology Solutions, explores how .
-
In , Steve Cutler comments on 91黑料’s success in decentralised trials and therapeutic technologies such as mRNA and checkpoint inhibitors.
-
Emily Mitchell, Executive Director, Decentralised Clinical Trials Operations and Christina Dinger, Director, Decentralised Clinical Trials Operations, run through .
This article was taken from Pharmafocus December 2021, pages 16-17. Samedan Ltd.
-
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
-
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
-
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
.jpg?w=340&itok=vvIkDfgO "IPT discussed in technical publications."){kind=icon}
